Welcome, Guest. Please login or register.
December 02, 2024, 09:07:52 am

Login with username, password and session length


Members
Stats
  • Total Posts: 55133
  • Total Topics: 4851
  • Online Today: 255
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 240
Total: 240

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Re-Treatment Regimens  (Read 6824 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Re-Treatment Regimens
« on: December 07, 2015, 02:36:06 pm »
Individuals who have failed hepatitis C virus treatment may ultimately achieve a cure if they add Sovaldi to a subsequent treatment regimen, show findings of two new studies presented at the AASLD's Annual Liver Meeting in San Francisco.

In one study, researchers treated patients for 12 weeks with Merck's NS5A inhibitor elbasvir plus the protease inhibitor grazoprevir, along with Gilead Sciences’ Sovaldi plus ribavirin. Cure rates were 100% for those who adhered to the regimen.

Then, in another study, 22 participants who had experienced viral failure or relapse after a first treatment attempt were treated with Viekira Pak plus Sovaldi and ribavirin.  Cure rates for that were 93%.

For more information: http://www.hepmag.com/articles/retreatment_QUARTZ_SWIFT_2501_28107.shtml

Offline Mike

  • Member
  • Posts: 999
Re: Re-Treatment Regimens
« Reply #1 on: December 07, 2015, 08:16:12 pm »
Thanks for the info!

Mike
Genotype 1a
Treated 2001 with PEG and RIBV
Treated in 2014 SOL+PEG+RIBV
Cured July 2014

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.